RenalGuard Therapy Gets Breakthrough Device Designation for Prevention of Cardiac Surgery Associated AKI
The FDA granted Breakthrough Device Designation for CardioRenal Systems' RenalGuard Therapy device for the prevention of acute kidney injury.
The FDA granted Breakthrough Device Designation for CardioRenal Systems' RenalGuard Therapy device for the prevention of acute kidney injury.
Noninvasix’s LIVOx Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the FDA for non-invasive Sepsis monitoring tech.
The ChEVAS System is an investigational endovascular abdominal aortic aneurysm (AAA) sealing therapy designed to combine the Nellix 3.5 endograft with parallel visceral stents to enable treatment of patients with juxtarenal, pararenal, and suprarenal AAA.
The FDA granted Breakthrough Device Designation for CardioRenal Systems' RenalGuard Therapy device for the prevention of acute kidney injury.